Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0091-6749(97)70181-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations.
Immun Inflamm Dis
December 2024
Medical Affairs and Clinical Department, LETI Pharma S.L.U., Madrid, Spain.
Background: Efficacy of allergen immunotherapy is dose-dependent; however, high doses of allergen may imply a greater risk of adverse reactions.
Objective: To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatophagoides pteronyssinus/Blomia tropicalis (Dpt/Bt) and Dermatophagoides pteronyssinus/Lepidoglyphus destructor (Dpt/Ld) at maximum concentrations, in adult patients with allergic rhinitis or rhinoconjunctivitis, and controlled allergic asthma due to a clinically relevant sensitisation to these mites.
Methods: An open-label, noncontrolled, nonrandomised, phase IIb clinical trial was carried out in three hospitals in Spain between September 2014 and May 2018.
Sensitisation to Lep d 2- Lepidoglyphus destructor allergy in asthma and rhinitis.
Eur Ann Allergy Clin Immunol
October 2024
Department of Immunoallergology, Arrábida Local Unit of Health, Hospital de São Bernardo, Setúbal, Portugal.
Article Synopsis
- Mites, especially Storage Mites (SM), play a significant role in allergic diseases like asthma and rhinitis, affecting about 1.5% of the global population, with a focus on their impact in urban areas, particularly the Mediterranean.
- The study examined patients monosensitised to the major allergen Lep d 2, using advanced allergy testing methods, finding that a notable percentage of these individuals primarily suffer from allergic rhinitis, with some also exhibiting asthma symptoms.
- Results indicate that sensitisation to Lep d 2, while showing lower sIgE levels compared to polysensitised patients, plays an important role in persistent allergic respiratory conditions, underlining the need
Assessment of sIgE to rLep d 2 for detecting Lepidoglyphus destructor sensitization.
Allergy
December 2024
Allergy Department, University Hospital of Salamanca, Salamanca, Spain.
Clinical Relevance of Lepidoglyphus destructor Sensitisation in Allergic Rhinitis: Nasal Provocation Test as in vivo Assessment.
Int Arch Allergy Immunol
May 2024
CICS- Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
Background: Dust mites are the leading cause of respiratory allergic diseases worldwide. Allergy to storage mites (SMs) has mostly been related to occupational exposures. However, recent studies have shown that sensitisation to SM, such as Lepidoglyphus destructor (Lep d), is of considerable importance also in urban populations, with high prevalence in dust samples of domestic environments.
View Article and Find Full Text PDFAtopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Int Arch Allergy Immunol
March 2024
Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
Introduction: The possible influence of sensitization to aeroallergens on omalizumab response in chronic spontaneous urticaria (CSU) has been insufficiently investigated. This study's aim was to investigate atopy's influence on omalizumab response in CSU patients.
Method: Retrospective study of CSU patients followed at a Portuguese Urticaria Center of Reference and Excellence (UCARE), treated with omalizumab for at least 6 months, between 2015 and 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!